Scarlet Therapeutics is developing a unique platform that generates novel red blood cell-based therapeutics to potentially treat a wide range of diseases. Initially targeted at the rare metabolic diseases, hyperammonemia and hyperoxaluria, this approach could also be used more broadly to target other metabolic diseases, cancer and autoimmune diseases. These therapeutic red blood cells (tRBCs) are very similar to standard red blood cells, having many unique qualities compared to systemic administration of therapeutic protein, including pervasive reach throughout the body, a long life and the ability to carry the active proteins within the tRBC, thereby shielding them from the immune system. Born out of more than a decade of research at the University of Bristol and its learnings from the RESTORE clinical study, Scarlet also has an exclusive commercial licence for the widely used BEL-A cell line, which provides an alternative platform technology for production of red blood cells.
Company Details
- Employees
- 13
- Founded
- -
- Address
- Midland Road, Bristol,united Kingdom
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://scarlet-tx.com/
- Keywords
- Bristol.
- HQ
- Bristol
Scarlet Therapeutics Ltd Questions
Scarlet Therapeutics Ltd's website is https://scarlet-tx.com/
Scarlet Therapeutics Ltd's LinkedIn profile is https://uk.linkedin.com/company/scarlet-therapeutics
Scarlet Therapeutics Ltd has
13 employees.
View email and phone details for 13
employees at Scarlet Therapeutics Ltd.
Scarlet Therapeutics Ltd's industry is
Biotechnology Research
Scarlet Therapeutics Ltd's top competitors are
Fluoretiq Limited,
Folium Science,
Isomab Ltd,
Science Creates,
Cytoseek,
Extracellular,
Kelpi,
Zentraxa,
Genomekey,
Exmoor Pharma.
Scarlet Therapeutics Ltd's categories are Biotechnology Research
Scarlet Therapeutics Ltd's founding year is 2022
